Gastrointestinal Drugs Advisory Committee,
Meeting on November 16, 2011, from 8 a.m. to 5 p.m. (Day 1 of 2)
Agenda: On November 16, 2011, the committee will discuss the design of clinical trials to evaluate the safety, efficacy, and durability of response with repeat treatment cycles of XIFAXAN (rifaximin), by Salix Pharmaceuticals, Inc., for irritable bowel syndrome with diarrhea.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment